卓新凤;

• 1:新乡市中医院药剂科

摘要(Abstract)：

目的探讨香丹注射液联合曲美他嗪片对冠心病心绞痛患者疗效及血清炎性因子的影响。方法选取我院收治的78例冠心病心绞痛患者作为研究对象,随机将其分为观察组及对照组,各39例。所有患者均给予硝酸甘油等药物进行常规治疗,对照组另口服给予曲美他嗪片,1片/次,3次/d;观察组在对照组治疗基础上给予香丹注射液(丹参、降香)治疗,1次/d。2组治疗时间均为2周。评价2组综合及心电图疗效。治疗前后,分别检测2组TG、TC、HDL-C及LDL-C等血脂指标,hs-CRP、TNF-α、IL-6及IL-8等炎性因子含量。结果观察组综合及心电图疗效评价中,总有效率分别为84.6%及87.2%,明显高于对照组(P<0.05);治疗后,观察组TG、TC、HDL-C及LDL-C水平分别为(2.27±0.63)mmol/L、(1.43±0.38)mmol/L、(2.12±0.27)mmol/L及(1.69±0.29)mmol/L,改善程度均明显优于对照组(P<0.05);治疗后,观察组hs-CRP、TNF-α、IL-6及IL-8含量分别为(57.4±11.2)ng/m L、(0.84±0.26)pg/m L、(29.6±7.7)ng/m L及(0.29±0.03)ng/m L,均明显低于对照组(P<0.05)。结论香丹注射液联合曲美他嗪片治疗冠心病心绞痛能明显提高治疗效果,改善血脂及炎性因子指标。

关键词(KeyWords)： 香丹注射液;曲美他嗪片;冠心病心绞痛;炎性因子

Abstract:

Keywords:

基金项目(Foundation): 河南省科学技术研究发展计划项目(0424410024)

作者(Author): 卓新凤;

Email:

DOI: 10.13463/j.cnki.jlzyy.2017.08.009

参考文献(References)：

• [1]PENG Song,ZHAO Min,WAN Jing,et al.The efficacy of trimetazidine on stable angina pectoris:a meta-analysis of randomized clinical trials[J].International Journal of Cardiology,2014,177(3):780-785.
• [2]XU Ming-zhu,YANG Xiang-jun.Double hazards of ischemia and reperfusion arrhythmias in a patient with variant angina pectoris[J].JOURNAL OF ELECTROCARDIOLOGY,2015,48(4):739-743.
• [3]D’SOUZA M,SARKISIAN L,SAABY L,et al.Diagnosis of unstable angina pectoris has declined markedly with the Advent of more sensitive troponin assays[J].The American Journal of Medicine,2015,128(8):852-860.
• [4]KIM M C,AHN Y,PARK K H,et al.Clinical outcomes of low-dose aspirin administration in patients with variant angina pectoris[J].International Journal of Cardiology,2013,167(5):2333-2334.
• [5]杨凯伦,徐一兰,殷佳,等.中医药干预PPARs及其通路治疗冠心病的研究进展[J].天津中医药,2016,33(8):503.
• [6]国际心脑病学会和协会WHO命名标准联合专题组.缺血性心脏病命名及诊断标准[J].中华心血管病杂志,1981,9(11):75-76.
• [7]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:6-36.
• [8]SARASTE A,UKKONEN H,VARIS A,et al.Effect of spinal cord stimulation on myocardial perfusion reserve in patients with refractory angina pectoris[J].European Heart JournalCardiovascular Imaging,2015,16(4):449-455.
• [9]BADAR A A,PEREZ-MORENO A C,JHUND P S,et al.Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction:an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure(CORONA)[J].European Heart Journal,2014,35(48):3426-3433.
• [10]KONG Dezhao,WANG Yang,LIU Yue,et al.The association between blood lipid and phlegm turbidity syndrome of angina pectoris:a systematic review and meta-analysis[J].Complementary Therapies in Medicine,2014,22(4):801.
• [11]唐召力,滕秋叶,覃碧云,等.养心氏片对冠心病患者心功能及超敏C反应蛋白的影响[J].中药药理与临床,2009,25(4):75-76.
• [12]袁肇凯,简维雄,黄献平,等.基于冠心病血瘀证心肌细胞能量代谢网络模型的血流平衡分析[J].湖南中医药大学学报,2016,36(2):20-24.
• [13]崔英子,高宏伟,王泽玉,等.参麦注射液在心内科合理应用即不良反应回顾性研究[J].长春中医药大学学报,2013,29(3):527-529.
• [14]仲伟琴,王保和.香丹葡萄糖注射液治疗冠心病心绞痛(心血瘀阻证)多中心临床观察[J].天津中医药大学学报,2007,26(1):14-16.
• [15]夏金根.香丹注射液辅治冠心病心绞痛的临床观察[J].临床合理用药杂志,2011,4(2):40-41.
• [16]王旭,张丽,朱瑾.香丹注射液治疗冠心病心绞痛的系统评价[J].新疆医科大学学报,2015,38(10):1257-1260.
• [17]谢芳.阿托伐他汀联合曲美他嗪治疗冠心病的疗效研究[J].实用心脑肺血管病杂志,2014,22(11):28-30.
• [18]冷玉杰.丹参煎剂对冠心病心绞痛患者血液流变学指标的影响[J].吉林中医药,2016,36(3):249-251,252.
• [19]ONG P,SIVANATHAN R,BORGULYA G,et al.Obesity,inflammation and brachial artery flow-mediated dilatation:therapeutic targets in patients with microvascular angina(cardiac syndrome X)[J].Cardiovascular Drugs and Therapy,2012,26(3):239-244.
• [20]MILITARU C,DONOIU I,CRACIUN A,et al.Oral resveratrol and Calcium fructoborate supplementation in subjects with stable angina pectoris:effects on lipid profi les,inflammation markers,and quality of Life[J].Nutrition(Burbank,Los Angeles County,Calif.),2013,29(1):178.
• [21]STRAZHESKO I D,TKACHEVA O N,AKASHEVA D U,et al.Atorvastatin therapy modulates telomerase activity in patients free of atherosclerotic cardiovascular diseases[J].Frontiers in Pharmacology,2016(7):347.